iX Biopharma Ltd. (SG:42C)
SGX:42C
Top Page
iX Biopharma Ltd.
(SGX:42C)
Select Model
Select Model
Rating:48Neutral
Price Target:
S$0.22
▲(55.71% Upside)
Action:ReiteratedDate:02/06/26
The score is held down primarily by very weak financial performance (persistent losses, high leverage, and negative cash flows). Technicals are a relative positive with price above key moving averages and a positive MACD, but valuation is constrained by loss-making earnings and no dividend support.
Positive Factors
Proprietary delivery platform
Owning the WaferiX sublingual wafer platform gives the company a durable product differentiation. A platform technology can be applied across multiple therapeutics, enabling recurring licensing, easier product extensions and manufacturing leverage that support long-term commercial scalability and partner interest.
Negative Factors
Persistent large losses
Very large and persistent net losses undermine retained capital and strategic flexibility. Over the medium term these losses pressure ability to self-fund R&D, regulatory submissions and commercial rollouts, forcing dependence on external financing which can dilute shareholders and constrain long-term planning.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary delivery platform
Owning the WaferiX sublingual wafer platform gives the company a durable product differentiation. A platform technology can be applied across multiple therapeutics, enabling recurring licensing, easier product extensions and manufacturing leverage that support long-term commercial scalability and partner interest.
Read all positive factors
iX Biopharma Ltd. (42C) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$212.84M
Dividend YieldN/A
Average Volume (3M)15.11M
Price to Earnings (P/E)―
Beta (1Y)0.04
Revenue Growth30.34%
EPS Growth17.14%
CountrySG
Employees35
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,038,243,700
10 Day Avg. Volume11,332,920
30 Day Avg. Volume15,113,843
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)38.32
Price to Sales (P/S)1.80
P/FCF Ratio-3.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
iX Biopharma Ltd. Business Overview & Revenue Model
Company Description
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and...
How the Company Makes Money
iX Biopharma generates revenue through the development and commercialization of its proprietary drug products, which include both prescription and over-the-counter medications. The company's revenue model includes direct sales of its products, lic...
iX Biopharma Ltd. Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
30
Negative
Cash Flow
20
Very Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.77M | 5.96M | 5.91M | 14.39M | 1.75M |
| Gross Profit | 2.04M | 1.05M | 2.32M | 12.29M | -382.00K |
| EBITDA | -8.96M | -8.68M | -8.51M | -2.84M | -10.79M |
| Net Income | -10.14M | -10.79M | -9.62M | -4.60M | -8.23M |
Balance Sheet | |||||
| Total Assets | 11.28M | 14.62M | 24.93M | 28.52M | 18.86M |
| Cash, Cash Equivalents and Short-Term Investments | 866.00K | 1.77M | 6.52M | 13.49M | 6.21M |
| Total Debt | 5.90M | 5.20M | 4.34M | 4.41M | 4.24M |
| Total Liabilities | 10.92M | 10.28M | 9.08M | 8.77M | 7.15M |
| Stockholders Equity | 365.00K | 4.34M | 15.85M | 19.74M | 11.71M |
Cash Flow | |||||
| Free Cash Flow | -3.96M | -6.84M | -8.36M | 2.92M | -8.90M |
| Operating Cash Flow | -3.76M | -6.55M | -7.66M | 3.12M | -8.35M |
| Investing Cash Flow | -201.00K | 1.06M | -695.00K | -5.62M | -507.00K |
| Financing Cash Flow | 3.12M | 724.00K | 1.42M | 9.79M | 10.02M |
iX Biopharma Ltd. Technical Analysis
Positive
0.14
Price Trends
0.20
Positive
0.16
Positive
0.10
Positive
Market Momentum
<0.01
Positive
50.40
Neutral
23.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:42C, the sentiment is Positive. The current price of 0.14 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.20, and above the 200-day MA of 0.10, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.40 is Neutral, neither overbought nor oversold. The STOCH value of 23.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:42C.
iX Biopharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
SG:42C
iX Biopharma Ltd.
0.20
0.18
842.86%
SG:1J5
Hyphens Pharma International Ltd.
0.32
0.04
16.67%
SG:BFK
Pharmesis International Ltd.
0.36
-0.15
-29.00%
SG:FRQ
Singapore Paincare Holdings Limited
0.09
-0.02
-14.71%
SG:MIJ
Alliance Healthcare Group Ltd.
0.16
0.05
53.47%
SG:9QX
Beverly JCG Ltd.
0.01
0.00
0.00%
iX Biopharma Ltd. Corporate Events
iX Biopharma Wins US$41 Million U.S. Contract to Advance Wafermine Pain Therapy
Feb 12, 2026
iX Biopharma has secured a US$40.95 million development contract from the U.S. Government, represented by the Defense Health Agency and Program Executive Office Operational Medical Systems, to advance its Wafermine sublingual ketamine wafer for ac...
iX Biopharma Wins US$41 Million U.S. Defense Contract for Non-Opioid Pain Drug
Feb 12, 2026
iX Biopharma has secured a US$40.95 million development contract from the U.S. Department of Defense to advance Wafermine, its patented sublingual ketamine wafer for acute moderate to severe pain, through Phase 3 clinical trials. The funding will ...
iX Biopharma to Raise At Least S$6 Million via Share Placement
Feb 12, 2026
iX Biopharma has entered into a placement agreement with Oversea-Chinese Banking Corporation to raise at least S$6 million through a non-underwritten share placement. The deal will see new ordinary shares offered at S$0.198 each to institutional a...
iX Biopharma Earns Third Spot on Singapore’s Fastest Growing Companies List
Jan 20, 2026
iX Biopharma has been named one of Singapore’s Fastest Growing Companies 2026 by The Straits Times and Statista, marking the third time it has received this recognition after earlier listings in 2023 and 2024, underscoring its strong revenue...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.